How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,308 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01855711

2013 Clinical Trials

122. A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01870895 Recruitment Status

2013 Clinical Trials

123. Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

difficile. Has a colostomy. Intraabdominal surgery within the last 60 days. Evidence of active, severe colitis. History of short gut syndrome or motility disorders. Requires the regular use of medications that affect bowel motility (e.g., metoclopramide, narcotics, loperamide). Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy). Planned surgery requiring perioperative antibiotics within 6 months of study enrollment. Life expectancy of < 12 months. Compromised immune system (...) Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

124. A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01896583 Recruitment Status : Completed First Posted : July 11, 2013 Last

2013 Clinical Trials

125. Nutritional Management of Children With Chronic Diarrhea

Summary: The study objective is to assess the growth, tolerance and efficacy of a complete amino acid-based medical food in children with chronic diarrhea. Condition or disease Intervention/treatment Phase Growth and Tolerance Infant Study Other: Experimental Infant Formula Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 19 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary (...) Nutritional Management of Children With Chronic Diarrhea Nutritional Management of Children With Chronic Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nutritional Management of Children

2013 Clinical Trials

126. Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2014 Clinical Trials

127. Risk Factors for Crohn's Disease of the Neo-Small Intestine in Ulcerative Colitis Patients with Total Proctocolectomy and Primary or Secondary Ileostomies. (PubMed)

trying of ileal pouch) and secondary ileostomy (SI, i.e., stoma created after pouch failure) and to evaluate factors associated with the development of CD of the neo-small intestine proximal to ileostomy.A total of 123 eligible patients were identified from our Pouch Center Registry (PI group, n = 57 and SI group, n = 66). Demographics, clinical features and outcomes (CD of theneo-small intestine, non-CD related strictures, requirement of CD-related medications use, ileostomy-associated (...) Risk Factors for Crohn's Disease of the Neo-Small Intestine in Ulcerative Colitis Patients with Total Proctocolectomy and Primary or Secondary Ileostomies. De novo Crohn’s disease (CD) of the neo-small intestine in ulcerative colitis (UC) patients after total proctocolectomy (TPC) is a new disease entity, which may persist even after a secondary diverting permanent ileostomy for pouch failure. We sought to compare outcomes of primary ileostomy (PI, i.e., stoma created after colectomy without

Full Text available with Trip Pro

2014 Journal of Crohn's & colitis

128. Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic – Induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MScPhm, ACPR, FCSHP Sabrina Boodhan BScPhm, ACPR Lillian Sung MD, PhD Carol Portwine MD, FRCPC, PhD Richard Hain MD Patricia McCarthy RN, (EC), MSc(A) Mark (...) and the expert consensus of the POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Group, the following classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients is recommended: Recommendation: The single antineoplastic agents provided in Table 1 have high, moderate, low or minimal emetogenic potential in children. Table 1: Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Given

2010 SickKids Supportive Care Guidelines

129. Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea

Fidaxomicin vs. Vancomycin for C. difficile Diarrhea: Fidaxomicin for C. difficile diarrhea Fidaxomicin in C. difficile Diarrhea - Wiki Journal Club Fidaxomicin in C. difficile Diarrhea From Wiki Journal Club (Redirected from ) Jump to: , Louie TJ, et al. "Fidaxomicin versus Vancomycin for Clostridium difficile Infection". The New England Journal of Medicine . 2011. 365(5):422-431. • • Contents Clinical Question In patients with Clostridium difficile -associated diarrhea, is treatment (...) with fidaxomicin non-inferior to vancomycin in terms of clinical cure? Bottom Line Fidaxomicin was noninferior to vancomycin in achieving rates of clinical cure among patients with Clostridium difficile -associated diarrhea and resulted in fewer recurrent infections. Major Points Clostridium difficile -associated diarrhea (CDAD) is a major adverse effect of antibiotic usage and its incidence is on the rise, particularly among hospitalized patients receiving broad-spectrum antibiotics. While the trial (2007

2011 Wiki Journal Club

130. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Technology Report Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary (...) Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses Issue 133 November 2010Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Cite as: Banerjee S, Brown A, McGahan L, Asakawa K, Hutton B, Clark M, Severn M, Sharma M, Cox JL. Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome

2011 EvidenceUpdates

131. Zarxio (filgrastim-sndz) - medical review

Zarxio (filgrastim-sndz) - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125553Orig1s000 MEDICAL REVIEW(S) Page 1 Secondary (Team Leader) Review Date February 3, 2015 From Albert Deisseroth, MD, PhD Subject Secondary Review BLA Number 125553 Applicant Sandoz Date of Submission May 8, 2014 PDUFA Goal Date March 8, 2015 Proprietary Name Zarxio Dosage Regimen 300 mcg/0.5 mL PFS, 480 mcg/0.8 mL PFS Approved Indications Patients with cancer receiving myelosuppressive (...) chemotherapy; Patients with AML receiving induction or consolidation chemotherapy; Patients with cancer receiving bone marrow transplant; Patients undergoing peripheral blood progenitor cell collection; Patients with severe chronic neutropenia. Recommendation: Approval of EP2006 as a biosimilar to US-licensed Neupogen for all 5 indications for which US-licensed Neupogen is currently licensed Material Reviewed/Consulted Reviewer/Author Medical Officer Review Donna Przepiorka, MD, PhD Clinical Pharmacology

2015 FDA - Drug Approval Package

132. Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01597505 Recruitment Status : Completed First Posted : May 14, 2012 Results First Posted : February 28, 2018 Last Update Posted

2012 Clinical Trials

133. Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

(mean) Secondary Outcome Measures : Evaluate the Clinical Outcome by Assessment of Clinical Response. [ Time Frame: Day 10 ] Positive clinical response defined as resolution of diarrhea Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. [ Time Frame: 28 days post-treatment ] Positive clinical response without recurrence through the follow-up period Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important (...) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2012 Clinical Trials

134. A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. Secondary Outcome Measures : Number of Clinical Failure Events up to Day 40 [ Time Frame: Up to 30 days after EOT (up to Day 40) ] The total number of clinical failure events, which included treatment failure, CDAD recurrence, death, or being lost to follow-up, occurring during each time period was determined in each arm. Adjusted (...) A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2012 Clinical Trials

135. Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea

to include fever and gross blood in stool, as well as report of no impact on activity AND, no treatment failure events to include the following: Recurrence of diarrheal illness meeting case definition of TD occurring within 72 hours after clinical cure Worsening of, or failure to improve after 24 hours of therapy Illness continuing after 72 hours Secondary Outcome Measures : Time to Last Unformed Stool [ Time Frame: 24, 48, 72 hours ] Calculated as the time from taking the first dose of study medication (...) , Naval Medical Research Center ClinicalTrials.gov Identifier: Other Study ID Numbers: IDCRP-065 First Posted: June 13, 2012 Last Update Posted: November 28, 2016 Last Verified: November 2016 Keywords provided by Mark Riddle, CDR, MC, USN, Naval Medical Research Center: diarrhea travelers' diarrhea watery diarrhea enteric illness dysentery gastrointestinal Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Fever Dysentery Signs and Symptoms, Digestive Signs and Symptoms Body

2012 Clinical Trials

136. Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants

Centro Pediatrico Albina Ptino More Information Go to Layout table for additonal information Responsible Party: Giuseppe Grandy, Medical Chief of Nutrition Center, Centro Pediatrico Albina de Patino ClinicalTrials.gov Identifier: Other Study ID Numbers: protzinc2012 First Posted: April 5, 2012 Last Update Posted: May 7, 2013 Last Verified: May 2013 Keywords provided by Giuseppe Grandy, Centro Pediatrico Albina de Patino: Acute Diarrhea Zinc Children Additional relevant MeSH terms: Layout table (...) Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Use

2012 Clinical Trials

137. Diarrhea and Oral Polio Vaccine Immunity

for poliovirus type 1 or 3 Seroconversion: proportion of children who change from seronegative to seropositive to types 1 or 3, four weeks after receipt of bOPV. Boost (increase in titer): seropositives at baseline who increase at least 4-fold in antibody titer four weeks after receipt of bOPV. Secondary Outcome Measures : Frequencies of enteric infections isolated in stool among infants with diarrhea vs. infants without diarrhea [ Time Frame: Date of enrollment ] One stool sample will be collected from each (...) Diarrhea and Oral Polio Vaccine Immunity Diarrhea and Bivalent Oral Polio Vaccine Immunity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diarrhea and Bivalent Oral Polio Vaccine Immunity The safety

2012 Clinical Trials

138. Efficacy of Racecadotril in Acute Watery Diarrhea in Children

Efficacy of Racecadotril in Acute Watery Diarrhea in Children Efficacy of Racecadotril in Acute Watery Diarrhea in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Racecadotril in Acute (...) Watery Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01577043 Recruitment Status : Completed First Posted : April 13, 2012 Last Update Posted : April 13, 2012 Sponsor: Centro Pediatrico Albina de Patino Information provided by (Responsible Party): Giuseppe Grandy, Centro

2012 Clinical Trials

139. Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

by C. difficile toxin assay. Wald 95% Confidence Intervals (CI) are presented. Secondary Outcome Measures : Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 60 Days Post-treatment. [ Time Frame: Up to 60 days post-treatment ] CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool (...) Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2012 Clinical Trials

140. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01736423 Recruitment Status : Completed First Posted : November 29, 2012 Last Update Posted : October 12, 2015 Sponsor

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>